Jaguar Gene’s JAG201 therapy trial for autism receives FDA approval

Jaguar Gene Therapy has received clearance from the US Food and Drug Administration (FDA) to administer JAG201, a gene replacement therapy, to both paediatric and adult patients in a Phase I clinical trial for autism.